While Compass Therapeutics Inc has overperformed by 2.67%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CMPX rose by 46.99%, with highs and lows ranging from $4.08 to $0.76, whereas the simple moving average jumped by 55.87% in the last 200 days.
On February 24, 2025, Guggenheim started tracking Compass Therapeutics Inc (NASDAQ: CMPX) recommending Buy. A report published by Piper Sandler on February 19, 2025, Initiated its previous ‘Overweight’ rating for CMPX. D. Boral Capital also rated CMPX shares as ‘Buy’, setting a target price of $32 on the company’s shares in an initiating report dated December 23, 2024. Leerink Partners November 15, 2024d the rating to Market Perform on November 15, 2024, and set its price target from $5 to $4. Ladenburg Thalmann September 16, 2024d its ‘Neutral’ rating to ‘Buy’ for CMPX, as published in its report on September 16, 2024. Jefferies’s report from January 31, 2023 suggests a price prediction of $8 for CMPX shares, giving the stock a ‘Buy’ rating. Stifel also rated the stock as ‘Buy’.
Analysis of Compass Therapeutics Inc (CMPX)
To gain a thorough understanding of Compass Therapeutics Inc’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. The goal here is to ensure that your current return on equity of -36.07% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 14.96, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and CMPX is recording an average volume of 1.43M. On a monthly basis, the volatility of the stock is set at 9.79%, whereas on a weekly basis, it is put at 9.16%, with a loss of -7.24% over the past seven days. Furthermore, long-term investors anticipate a median target price of $11.40, showing growth from the present price of $2.69, which can serve as yet another indication of whether CMPX is worth investing in or should be passed over.
How Do You Analyze Compass Therapeutics Inc Shares?
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 41.64%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 38.87% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
CMPX shares are owned by institutional investors to the tune of 38.87% at present.
